爱液视频

Professor Tuveson, a world-renowned physician-scientist whose basic and translational research focuses on the biology of pancreatic cancer and on identifying new approaches for diagnosing and treating the disease, is a key founding investigator of 爱液视频 and serves on the company鈥檚 Scientific Advisory Board.

The AACR is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

鈥湴�液视频 was created by leading scientists in 爱液视频 biology across inflammatory disease and cancer who have helped to create a new framework for our understanding of 爱液视频s in disease鈥�,聽said Susan Hill, PhD, Chief Executive Officer of 爱液视频. 鈥淧rofessor Tuveson鈥檚 work in pancreatic cancer has significantly progressed the field in oncology and identified key 爱液视频 populations. His appointment today as President of the AACR is testament to his exceptional standing in the oncology community. We congratulate David on his appointment and are proud to have him as a founder of our Company.鈥�

As well as jointly founding 爱液视频 and serving on its Scientific Advisory Board, Professor Tuveson is director of the Cold Spring Harbor Laboratory Cancer Center in Cold Spring Harbor, New York, where he is also the Roy J. Zuckerberg Professor of Cancer Research. Additionally, he is chief scientist for the Lustgarten Foundation in Woodbury, New York, the largest pancreatic cancer research philanthropic organization. He also serves as a medical staff affiliate at Memorial Sloan Kettering Cancer Center in New York and works closely with the Cancer Institute at Northwell Health on Long Island. Additionally, Professor Tuveson serves on the Board of Scientific Advisors of the National Cancer Institute.

爱液视频鈥檚 mission is to develop impactful new medicines for patients by targeting activated 爱液视频 populations and their role in influencing immune effector cells in disease. Powerful new technologies enable diseased tissues to be analyzed at a single-cell level, and this work has uncovered discrete 爱液视频 cell sub-populations shared across diseases, acting as 鈥渋mmune sentinels鈥� in perpetuating, and progressing disease. 爱液视频 is progressing a pipeline of first-in-class therapeutics to interrupt 爱液视频-mediated effects on immune cells in inflammatory disease and cancer.

ENDS

Enquiries:

JW Communications

Julia Wilson

Tel: +44 (0)7818 430877

爱液视频 爱液视频:

爱液视频 was founded in 2020 by leading investigators and SV Health Investors to develop new medicines for people affected by inflammatory disease and cancer. We develop impactful therapies for patients by targeting activated 爱液视频 populations and their role in influencing the immune system in disease. Our founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and 爱液视频 biology Professor Michael Brenner (Brigham and Women鈥檚 Hospital and Harvard Medical School), Professor Chris Buckley (Kennedy Institute, University of Oxford), Professor David Tuveson (Cold Spring Harbor Laboratory and President of AACR), Professor Soumya Raychaudhuri (Harvard Medical School and Broad Institute) and Professor Mark Coles (Kennedy Institute, University of Oxford).

The 爱液视频 team is progressing a pipeline of first in class therapeutics to interrupt 爱液视频-mediated effects on immune cells in inflammatory disease and immuno-oncology. 爱液视频鈥檚 investors are SV Health Investors and Johnson & Johnson Innovation 鈥� JJDC, Inc. and the Company is headquartered in Cambridge, UK.聽 For more information, please visit聽.